Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636858 | 0.90 | EPHX2 (0.54) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| Dezinamide SCHEMBL635558 | 0.90 | SLC6A2 (0.54) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1010840 | 0.88 | EPHX2 (0.59) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9595992 | 0.87 | EPHX2 (0.54) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL2636993 | 0.86 | EPHX2 (0.58) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2636375 | 0.84 | ABHD6 (0.50) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2637358 | 0.82 | LIPG (0.41) | ABHD6MGLLTP53ACACBCHRM3 | |
| SCHEMBL9596930 | 0.81 | ABHD6 (0.50) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9596860 | 0.81 | ABHD6 (0.50) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9596614 | 0.81 | ABHD6 (0.50) | ABHD6MGLLSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | claimed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | claimed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | ABHD6 2307/4885MGLL 2720/4885SLC6A2 100/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | ABHD6 136/4885MGLL 169/4885SLC6A2 4356/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | ABHD6 2307/4885MGLL 2720/4885SLC6A2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.